Wk chg

1/20 cls

Amgen Inc. (NASDAQ:AMGN)


Christopher Raymond

Price target

Market outperform



Raymond raised his target to $75 from $67 after "very positive" feedback from a November survey of 98 oncologists indicated that his estimates for denosumab were too low. The human mAb targeting receptor activator of NF-kappa B ligand (RANKL) is approved as Prolia in the EU and U.S. to treat osteoporosis in postmenopausal women and in the EU to treat bone loss associated with hormone ablation in men with prostate cancer. It is also approved as Xgeva in the U.S. and EU to prevent skeletal related events in adults with bone metastases.

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL)

RBC Capital Markets

Michael Yee


Outperform (from sector perform)



Yee also raised his target to $26 from $20 ahead of Phase III data anticipated next quarter for Xiaflex collagenase clostridium histolyticum for Peyronie's disease. Yee models a 70% chance of positive data from the trial, which he said could drive the stock up to $30. Yee also notes that Auxilium's new CEO, Adrian Adams, has sold three companies and if the Peyronie's data is positive, the company would be an attractive takeout. Auxilium has worldwide rights to the injectable form of collagenase from BioSpecifics Technologies Corp. (NASDAQ:BSTC).